Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Characterizing MRI features of rectal cancers with different KRAS status.
|
31727020 |
2019 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KLF5 was significantly associated with the presence of KRAS mutations, and KLF5 was an independent poor response predictor of CRT in rectal cancer.
|
31388510 |
2019 |
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
KRAS status has no difference between colon cancer and rectal cancer.
|
30917791 |
2019 |
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
DKI metrics with whole-tumor volume histogram analysis is associated with KRAS mutations, and thus may be useful for predicting the KRAS status of rectal cancers for guiding targeted therapy.
|
30637861 |
2019 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).
|
29241084 |
2018 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Carriers of the homozygous variant genotype TT for rs712 in KRAS gene were associated with a decreased risk of rectal cancer (odds ratio (OR) = 0.65, 95% confidence intervals (CI) 0.43-1.00, P = 0.05) while individuals with colon cancer carrying the heterozygous GT genotype showed a longer overall survival (OS) (P = 0.04).
|
29048575 |
2017 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Differences of protein expression profiles, KRAS and BRAF mutation, and prognosis in right-sided colon, left-sided colon and rectal cancer.
|
28801584 |
2017 |
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
KRAS mt status may affect the prognosis of early rectal cancer, as this is linked with distant recurrence.
|
28314302 |
2017 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics.
|
27184911 |
2016 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutation status analyses were performed in 199 tumor samples from 47 patients with rectal cancer.
|
27064574 |
2016 |
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
|
27020587 |
2016 |
Rectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
|
26831663 |
2016 |
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the tumor response and survival according to the KRAS oncogene status in locally advanced rectal cancer.
|
26252300 |
2015 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.
|
26162609 |
2015 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
[(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study.
|
25899481 |
2015 |
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer.
|
25304881 |
2015 |
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this prospective study was to analyse the association between infection of a tumour by HCMV and EBV and clinical, histological, metabolic ((18)F-FDG uptake), volumetric (from CT) and molecular (KRAS status) features and long-term outcomes in a homogeneously treated group of patients with locally advanced rectal cancer.
|
25269837 |
2015 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using a database of 735 colon and rectal cancers in the Nurse's Health Study and the Health Professionals Follow-up Study, we examined the relationship of tumor SMO expression (assessed by immunohistochemistry) to prognosis, and to clinical, pathological, and tumor molecular features, including mutations of KRAS, BRAF, and PIK3CA, microsatellite instability, CpG island methylator phenotype (CIMP), LINE-1 methylation, and expression of phosphorylated AKT and CTNNB1.
|
25023548 |
2014 |
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The accuracy of SUVmax for predicting mutated KRAS was higher in patients with colon or sigmoid colon cancers, whereas it was TW40% in those with rectal cancers.
|
24978328 |
2014 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study is the first to compare different SMIs in combination with IR for the treatment of K-RAS mutant rectal cancer, and our findings suggest that Chk1/2 inhibitors should be evaluated in new clinical trials for LARC.
|
24349411 |
2013 |
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study has identified a subgroup of more aggressive rectal cancers that may arise through the KRAS-p16 pathway.
|
24259266 |
2014 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our objective was to establish a correlation between specific KRAS mutations and rectal cancer response to CRT and to investigate if the correlation was related to a different association between KRAS and TP53 mutations.
|
23456389 |
2013 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
|
22672749 |
2013 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our objective was to explore the relationships of KRAS and BRAF mutation status with p-AKT and p-ERK and outcomes in RC.
|
21910869 |
2011 |
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The identified MSI and KRAS mutational prevalences parallel those reported in the rectal cancer literature.
|
21836482 |
2011 |